Carbohydrate antigen 19-9 – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 28 May 2026 11:30:03 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Carbohydrate antigen 19-9 – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of drug combination therapy after surgery in patients with resectable pancreatic ductal adenocarcinoma using lab-grown mini-tumors to guide treatment selection https://clinicaltrials.eu/trial/study-of-drug-combination-therapy-after-surgery-in-patients-with-resectable-pancreatic-ductal-adenocarcinoma-using-lab-grown-mini-tumors-to-guide-treatment-selection/ Wed, 29 Apr 2026 15:07:21 +0000 https://clinicaltrials.eu/trial/study-of-drug-combination-therapy-after-surgery-in-patients-with-resectable-pancreatic-ductal-adenocarcinoma-using-lab-grown-mini-tumors-to-guide-treatment-selection/ This study focuses on patients with pancreatic ductal adenocarcinoma (PDAC) who have had surgery to remove their tumor. The research aims to use laboratory-grown miniature versions of tumors, called organoids, created from patients’ cancer tissue to predict which chemotherapy treatment will work best for each individual after surgery.

The study involves several chemotherapy medications that are commonly used to treat pancreatic cancer. These include capecitabine, paclitaxel, irinotecan, gemcitabine, fluorouracil, oxaliplatin, and calcium folinate. Some medications are given by mouth, while others are administered through an intravenous line. The treatment period typically lasts for 6 months.

The research is divided into two parts. The first part checks if it’s possible to grow these mini-tumors and test different chemotherapy combinations on them within 12 weeks after surgery. The second part examines how well patients do when their treatment is chosen based on how their laboratory-grown tumor responds to different chemotherapy combinations. The effectiveness of the treatment will be measured by tracking how long patients remain free of cancer after treatment.

]]>